MonoSol Rx Announces FDA Approval of Zuplenz® Oral Soluble Film Medication – Stops and Prevents Nausea with Chemother
Posted Jul 07 2010 6:10pm
The medication is given in a film format the dissolves in your mouth, thus no need for water. The drug is to be used for the prevention of Chemotherapy-induced, Radiotherapy-induced, and Postoperative Nausea and Vomiting. For cancer patients needing treatment from the drug, this could make therapy with chemo and radiation treatments a little easier to stop the nausea without having to dump another medication into the IV. This is the first such drug approved by the FDA in this delivery system. BD
From the website:
“ MonoSol Rx is a leading drug delivery company specializing in the development and commercialization of thin film pharmaceutical and over-the-counter (OTC) drug products. The Company’s thin film formulations offer significant patient benefits, including convenience, taste and potentially greater efficacy. Each thin film strip is small in size — about the size of a postage stamp, utilizes drug taste-masking technology and dissolves rapidly in the mouth without the need for water”
WARREN, N.J. and BALERNA, Switzerland, July 7 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR") and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX ), has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® (ondansetron) oral soluble film ("OSF") for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz is the first oral soluble film product approved by the FDA as a prescription medication.